Xinglin Wu

1.3k total citations · 1 hit paper
25 papers, 957 citations indexed

About

Xinglin Wu is a scholar working on Molecular Biology, Infectious Diseases and Surgery. According to data from OpenAlex, Xinglin Wu has authored 25 papers receiving a total of 957 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 6 papers in Infectious Diseases and 5 papers in Surgery. Recurrent topics in Xinglin Wu's work include HIV/AIDS drug development and treatment (6 papers), HIV Research and Treatment (5 papers) and Orthopaedic implants and arthroplasty (2 papers). Xinglin Wu is often cited by papers focused on HIV/AIDS drug development and treatment (6 papers), HIV Research and Treatment (5 papers) and Orthopaedic implants and arthroplasty (2 papers). Xinglin Wu collaborates with scholars based in United States, China and Canada. Xinglin Wu's co-authors include Max Hallin, David A. Rewolinski, David R. Shalinsky, Helen Y. Zou, Steve Bender, Shinji Yamazaki, Grant Wickman, Dana D. Hu‐Lowe, Robert S. Kania and Jeffrey H. Chen and has published in prestigious journals such as Journal of Virology, Clinical Cancer Research and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Xinglin Wu

24 papers receiving 940 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3

2008 515 citations Dana D. Hu‐Lowe, Helen Y. Zou et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Xinglin Wu United States	10	406	292	259	155	148	25	957
Zaina T. Al-Salama New Zealand	17	322 0.8×	174 0.6×	262 1.0×	100 0.6×	95 0.6×	35	1.0k
Marco H. Hofmann Austria	13	489 1.2×	123 0.4×	301 1.2×	96 0.6×	129 0.9×	41	953
Prabhu Rajagopalan United States	17	365 0.9×	252 0.9×	360 1.4×	72 0.5×	81 0.5×	51	1.1k
Kentaro Watanabe Japan	17	369 0.9×	159 0.5×	58 0.2×	193 1.2×	71 0.5×	77	1.2k
Lucille Leong United States	23	502 1.2×	265 0.9×	691 2.7×	73 0.5×	170 1.1×	74	1.6k
Sharon Diamond United States	12	348 0.9×	95 0.3×	184 0.7×	168 1.1×	35 0.2×	21	1.0k
Hui‐Ping Hsu Taiwan	24	695 1.7×	293 1.0×	489 1.9×	68 0.4×	384 2.6×	67	1.5k
Kenneth Steadman United States	16	543 1.3×	160 0.5×	611 2.4×	122 0.8×	101 0.7×	28	1.1k
Maria Rius Germany	18	520 1.3×	244 0.8×	711 2.7×	90 0.6×	83 0.6×	22	1.5k
Aurora González‐Fierro Mexico	21	1.0k 2.5×	127 0.4×	266 1.0×	69 0.4×	233 1.6×	46	1.5k

Countries citing papers authored by Xinglin Wu

Since Specialization

Citations

This map shows the geographic impact of Xinglin Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xinglin Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xinglin Wu more than expected).

Fields of papers citing papers by Xinglin Wu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xinglin Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xinglin Wu. The network helps show where Xinglin Wu may publish in the future.

Co-authorship network of co-authors of Xinglin Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Xinglin Wu. A scholar is included among the top collaborators of Xinglin Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xinglin Wu. Xinglin Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wu, Xinglin, Sarah Macklin, Yanling Zhang, et al.. (2025). Induction of proximal tubular proliferation and lengthening in response to sodium glucose linked cotransporter‐2 inhibition in experimental rats. Journal of Diabetes Investigation. 16(7). 1232–1242.

Wu, Xinglin, et al.. (2024). Preparation, Characterization, and Bioactivities of Cobalt, Strontium and Fluorine Co-Doped Oxide Films on Titanium Surface for Clinical Application. Journal of Biomedical Nanotechnology. 20(4). 678–686. 2 indexed citations

Li, Yankun, et al.. (2023). Clinical effects of 3D printing-assisted posterolateral incision in the treatment of ankle fractures involving the posterior malleolus. Frontiers in Surgery. 10. 1176254–1176254. 1 indexed citations

Wu, Xinglin, et al.. (2023). TNF-α activates RELA expression via TNFRSF1B to upregulate OPA1 expression and inhibit chondrogenic differentiation of human adipose stem cells. Journal of Orthopaedic Surgery and Research. 18(1). 430–430. 2 indexed citations

Wu, Xinglin, et al.. (2023). Long non-coding RNA MIR22HG suppresses the chondrogenic differentiation of human adipose-derived stem cells by interacting with CTCF to upregulate CRLF1. Functional & Integrative Genomics. 23(4). 329–329. 2 indexed citations

Zheng, Hongming, Li Xu, Xia Yan, et al.. (2023). Fabrication and surface characterization of titanium dioxide nanotubes on titanium implants. Frontiers in Materials. 10. 1 indexed citations

Connelly, Kim A., Xinglin Wu, Mark K. Friedberg, et al.. (2022). The SGLT2i Dapagliflozin Reduces RV Mass Independent of Changes in RV Pressure Induced by Pulmonary Artery Banding. Cardiovascular Drugs and Therapy. 38(1). 57–68. 9 indexed citations

Wu, Lingling, Bharat Narasimhan, Kirtipal Bhatia, et al.. (2022). One year outcomes of atrial fibrillation ablation: Contemporary analysis of the United States Nationwide Readmission Database. Pacing and Clinical Electrophysiology. 45(9). 1151–1159. 2 indexed citations

Fan, Longxing, Wentao Liu, Yingchun Zhang, et al.. (2021). A highly sensitive method for simultaneous detection of hAAG and UDG activity based on multifunctional dsDNA probes mediated exponential rolling circle amplification. Talanta. 232. 122429–122429. 12 indexed citations

10.

Sun, Tieqiang, Wentao Liu, Longxing Fan, et al.. (2021). Simultaneous detection of diethylstilbestrol and estradiol residues with a single immunochromatographic assay strip. Food Science & Nutrition. 9(3). 1824–1830. 19 indexed citations

11.

Zhang, Yanling, Kim A. Connelly, Kerri Thai, et al.. (2016). Sirtuin 1 Activation Reduces Transforming Growth Factor-β1–Induced Fibrogenesis and Affords Organ Protection in a Model of Progressive, Experimental Kidney and Associated Cardiac Disease. American Journal Of Pathology. 187(1). 80–90. 53 indexed citations

12.

Smith, Bill J., Yazdi K. Pithavala, Hai‐Zhi Bu, et al.. (2014). Pharmacokinetics, Metabolism, and Excretion of [14C]Axitinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Humans. Drug Metabolism and Disposition. 42(5). 918–931. 31 indexed citations

13.

Wu, Xinglin, et al.. (2013). Relation between signal-noise-ratio of UV image intensifier and voltage of MCP. Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE. 8761. 87610T–87610T. 1 indexed citations

14.

Haznedar, Joshua, Shem Patyna, Carlo L. Bello, et al.. (2009). Single- and multiple-dose disposition kinetics of sunitinib malate, a multitargeted receptor tyrosine kinase inhibitor: comparative plasma kinetics in non-clinical species. Cancer Chemotherapy and Pharmacology. 64(4). 691–706. 56 indexed citations

15.

Hu‐Lowe, Dana D., Helen Y. Zou, Maren L. Grazzini, et al.. (2008). Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3. Clinical Cancer Research. 14(22). 7272–7283. 515 indexed citations breakdown →

16.

Bu, Hai‐Zhi, Ping Zhao, Ping Kang, et al.. (2007). Evaluation of Capravirine as a CYP3A Probe Substrate: In Vitro and in Vivo Metabolism of Capravirine in Rats and Dogs. Drug Metabolism and Disposition. 35(9). 1593–1602. 2 indexed citations

17.

Younis, Husam S., Bart Jessen, Xinglin Wu, & Gregory J. Stevens. (2006). Inhibiting matrix metalloproteinases with prinomastat produces abnormalities in fetal growth and development in rats. Birth Defects Research Part B Developmental and Reproductive Toxicology. 77(2). 95–103. 8 indexed citations

18.

Wu, Xinglin, Amy K. Patick, Bradley M. Kerr, et al.. (2001). Circulating Metabolites of the Human Immunodeficiency Virus Protease Inhibitor Nelfinavir in Humans: Structural Identification, Levels in Plasma, and Antiviral Activities. Antimicrobial Agents and Chemotherapy. 45(8). 2405–2405. 1 indexed citations

19.

Wu, Xinglin, et al.. (1997). High-performance liquid chromatographic method for the determination of nelfinavir, a novel HIV-1 protease inhibitor, in human plasma. Journal of Chromatography B Biomedical Sciences and Applications. 695(2). 373–380. 66 indexed citations

20.

Wu, Xinglin, et al.. (1988). Metabolic studies on the nigrostriatal toxin MPTP and its MAO B generated dihydropyridinium metabolite MPDP+. Chemical Research in Toxicology. 1(3). 186–194. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact